| 仑伐替尼治疗肝细胞癌的研究进展 |
| |
| 引用本文： | 姜仲春,谷带利,唐才喜,谢智钦. 仑伐替尼治疗肝细胞癌的研究进展[J]. 中国肿瘤临床, 2021, 48(7): 371-375. DOI: 10.3969/j.issn.1000-8179.2021.07.222 |
| |
| 作者姓名： | 姜仲春 谷带利 唐才喜 谢智钦 |
| |
| 作者单位： | 中南大学湘雅医学院附属株洲医院肝胆胰脾外科（湖南省株洲市412007） |
| |
| 基金项目： | 湖南省自然科学基金2017JJ4070湖南省自然科学青年基金2020JJ5998湖南省科技计划项目2016SK4006株洲市2019年科技人才托举项目2019TJ-07 |
| |
| 摘 要： | 肝细胞癌（hepatocellular carcinoma，HCC）是严重威胁人类生命健康的疾病之一，其发病率和死亡率逐年上升，具有发展迅速、高侵袭性和高复发性等特点。大多数患者确诊时已是进展期，而靶向治疗作为进展期肝癌的主要治疗策略，已广泛应用于临床。以往该类患者的一线治疗药物仅有索拉菲尼，但其不良反应大，肿瘤应答率低，对乙型肝炎病毒（hepatitis B virus，HBV）阳性患者的总生存率并无明显改善。近年来，新的靶向治疗药物仑伐替尼在肝癌的治疗研究中取得了良好的疗效，成为继索拉菲尼后治疗进展期肝癌的第2个一线药物。本文就仑伐替尼在治疗HCC中的研究进展进行综述。
|
| 关 键 词： | 仑伐替尼 肝细胞癌 治疗 |
| 收稿时间： | 2020-10-02 |
Advances of lenvatinib in the treatment of hepatocellular carcinoma |
| |
| Affiliation: | Department of Hepatobiliary and Pancreatic Surgery, Zhuzhou Hospital Affiliated to Xiangya School of Medicinel, Zhuzhou 412007, China |
| |
| Abstract: | Hepatocellular carcinoma (HCC) is one of the disease that threaten human life and health, and its morbidity and mortality are increasing annually. It has the characteristics of rapid development, high invasiveness, and a high recurrence rate. Most patients present with advanced stage disease at the time of diagnosis, and targeted therapy is the main treatment strategy for advanced HCC in clinical practice. Sorafenib, which was once the only first-line therapeutic agent for unresectable HCC patients, has significant side effects, a low tumor response rate, and does not improve the overall survival of hepatitis B virus-positive patients. In recent years, a new targeted drug, lenvatinib, has been reported to show good efficacy in the treatment of HCC and has become the second first-line drug after sorafenib. In this article, we review the progress of research on the use of lenvatinib in the treatment of HCC. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
